Literature DB >> 18246097

New drug targets in inflammation: efforts to expand the anti-inflammatory armoury.

S G Ward1.   

Abstract

Inflammation is a beneficial host response to challenge by foreign bodies or to tissue injury. When this normal physiological process (which is designed to restore normal tissue structure and function), becomes dysregulated, it can become harmful and destructive leading to inflammatory diseases that are a major burden on humanity. Despite some notable successes, there are still major unmet medical needs in the treatment of inflammatory diseases and the development of new anti-inflammatory drugs features prominently in the research portfolios of most pharmaceutical and biotech companies. New insights into inflammatory processes and new anti-inflammatory drug targets were the subjects of a Focus Topic organized for the Life Sciences 2007 meeting in Glasgow (July 2007). The speakers from this meeting were invited to generate reviews on the basis of their presentations and these reviews contribute to this themed issue and are summarized in this short article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246097      PMCID: PMC2268037          DOI: 10.1038/sj.bjp.0707628

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

Review 1.  Inflammatory resolution: new opportunities for drug discovery.

Authors:  Derek W Gilroy; Toby Lawrence; Mauro Perretti; Adriano G Rossi
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

Review 2.  Targeting signal transduction as a strategy to treat inflammatory diseases.

Authors:  Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2006-06-09       Impact factor: 84.694

Review 3.  Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.

Authors:  C N Serhan; N Chiang
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 4.  The mechanisms, diagnosis, and management of severe asthma in adults.

Authors:  Stephen T Holgate; Riccardo Polosa
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

Review 5.  Biologic therapies in rheumatology: lessons learned, future directions.

Authors:  Vibeke Strand; Robert Kimberly; John D Isaacs
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

Review 6.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs.

Authors:  Dairong Wang; Dairong Wong; Miao Wang; Yan Cheng; Garret A Fitzgerald
Journal:  Curr Opin Pharmacol       Date:  2005-04       Impact factor: 5.547

Review 7.  Does safety make a difference in selecting the right TNF antagonist?

Authors:  Roy Fleischmann; David Yocum
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

8.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

Review 9.  Fibroblasts as novel therapeutic targets in chronic inflammation.

Authors:  S J Flavell; T Z Hou; S Lax; A D Filer; M Salmon; C D Buckley
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

10.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Authors:  Joel M Kremer; Rene Westhovens; Marc Leon; Eduardo Di Giorgio; Rieke Alten; Serge Steinfeld; Anthony Russell; Maxime Dougados; Paul Emery; Isaac F Nuamah; G Rhys Williams; Jean-Claude Becker; David T Hagerty; Larry W Moreland
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

View more
  5 in total

1.  Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis.

Authors:  L Antonioli; A El-Tayeb; C Pellegrini; M Fornai; O Awwad; G Giustarini; G Natale; L Ryskalin; Z H Németh; C E Müller; C Blandizzi; R Colucci
Journal:  Purinergic Signal       Date:  2017-11-08       Impact factor: 3.765

2.  NG2 glia regulate brain innate immunity via TGF-β2/TGFBR2 axis.

Authors:  Shu-Zhen Zhang; Qin-Qin Wang; Qiao-Qiao Yang; Huan-Yu Gu; Yan-Qing Yin; Yan-Dong Li; Jin-Can Hou; Rong Chen; Qing-Qing Sun; Ying-Feng Sun; Gang Hu; Jia-Wei Zhou
Journal:  BMC Med       Date:  2019-11-15       Impact factor: 8.775

3.  Possible therapeutic effect of trilostane in rodent models of inflammation and nociception.

Authors:  David Tung; John Ciallella; Heather Hain; Peter H Cheung; Saurabh Saha
Journal:  Curr Ther Res Clin Exp       Date:  2013-12

4.  Repositioning drugs for inflammatory disease - fishing for new anti-inflammatory agents.

Authors:  Christopher J Hall; Sophie M Wicker; An-Tzu Chien; Alisha Tromp; Lisa M Lawrence; Xueying Sun; Geoffrey W Krissansen; Kathryn E Crosier; Philip S Crosier
Journal:  Dis Model Mech       Date:  2014-07-18       Impact factor: 5.758

Review 5.  Protective Role of St. John's Wort and Its Components Hyperforin and Hypericin against Diabetes through Inhibition of Inflammatory Signaling: Evidence from In Vitro and In Vivo Studies.

Authors:  Michela Novelli; Pellegrino Masiello; Pascale Beffy; Marta Menegazzi
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.